Feed - Buzzberg

17:00
Jul 23 ◎

EW FY2026 Q2 Watch

Edwards Lifesciences Corporation (EW) FY2026 Q2 Earnings Call

EW ▾

Bernard Zovighian

Management raised full-year guidance across all segments, citing durable competitive advantages in TAVR and accelerating TMTT portfolio adoption, signaling confidence in sustained mid-to-high single-digit TAVR growth and 10% total company growth long-term.

"We delivered stronger than expected second quarter sales growth of 12.5%."

EW WATCH

HIGH

14:00
Apr 23 ◎

EW FY2026 Q1 Watch

Edwards Lifesciences Corporation (EW) FY2026 Q1 Earnings Call

EW ▾

Bernard Zavigian

Management raised full-year guidance across total company, TAVR, and EPS, citing strong Q1 momentum and broad-based growth, signaling improving confidence in the durable multi-year growth trajectory.

"We are raising our full year 2026 sales growth guidance to 9% to 11% and adjusted EPS guidance to $2.95 to $3.05"

EW WATCH

HIGH

17:00
Feb 10 ◎

EW FY2025 Q4 Watch

Edwards Lifesciences Corporation (EW) FY2025 Q4 Earnings Call

EW ▾

Bernard Zavigian

Management expressed heightened confidence in 2026 guidance (8-10% sales growth, $2.90-$3.05 EPS) citing strong Q4 momentum, multiple growth catalysts, and durable evidence-driven tailwinds.

"We have increased confidence in our top-line and bottom-line guidance for 2026."

EW WATCH

HIGH

17:00
Oct 30 ◎

EW FY2025 Q3 Watch

Edwards Lifesciences Corporation (EW) FY2025 Q3 Earnings Call

EW ▾

Bernard Zavigian

Management raised full-year guidance on the back of stronger-than-expected Q3, citing renewed clinical focus on TAVR and positive data; tone is confident about sustainable multi-year growth.

"we are raising full-year sales growth guidance to the high end of the previous 9% to 10% range and are also raising our EPS guidance range to between $2.56 and $2.62."

EW WATCH

HIGH

Feed — Buzzberg